$ 28.02
Key Takeaways
Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus,...
Company Valuation
From both historical and forecast perspectives, the stock is slightly overpriced compared to similar stocks. In particular, the stock is overvalued on P/FCF.
Target Price
The average target price of MRNA is 44 and suggests 59% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
